Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Grant of Warrants to Employees in Genmab14 Oct 2011
Report Pursuant to Section 28a of the Danish Securities Trading Act14 Oct 2011
Genmab to Present at Two Investor Conferences in September7 Sept 2011
Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Chemotherapy in Second Line Aggressive Lymphoma5 Aug 2011
Interim Report for the 6 months ended June 30, 20113 Aug 2011
Genmab Announces Financial Results for the First Half of 2011 and Improved Guidance3 Aug 2011
Arzerra Second Quarter 2011 Net Sales Figures26 Jul 2011
Articles of Association of Genmab A/S
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
1 Jul 2011
Genmab Announces Zalutumumab Update24 Jun 2011
Grant of Warrants to Board Members, Management and Employees in Genmab22 Jun 2011
Report Pursuant to Section 28a of the Danish Securities Trading Act22 Jun 2011
Genmab to Attend Two June Investor Conferences25 May 2011
  • Previous
  • 1
  • More pages
  • 95
  • 96
  • 97
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863